{"created":"2023-06-20T16:49:49.856221+00:00","id":22134,"links":{},"metadata":{"_buckets":{"deposit":"79f1e63e-e347-4ebc-bfda-6d461d1c444d"},"_deposit":{"created_by":3,"id":"22134","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"22134"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00022134","sets":["14:2667:4710"]},"author_link":["3128"],"control_number":"22134","item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"11","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2020)"}]}]},"item_8_description_25":{"attribute_name":"リンクURL","attribute_value_mlt":[{"subitem_description":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K06769/","subitem_description_type":"Other"}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：臨床において、網膜障害は失明に繋がる重篤な問題である。我々は、点眼による網膜治療を目指し、湿式ビーズミル法を用い、ニルバジピン（NIL）ナノ結晶点眼製剤を作製した（粒子径77 nm）。本製剤を右目に点眼したところ、高い後眼部移行性が確認できた。また、非点眼群（左眼）では、網膜中での薬物検出はわずかであったことから、これら点眼後の眼後部への薬物移行は局所的であることが確認できた。さらに、このナノ製剤の点眼により、糖尿病モデル（STZラット）の低下した網膜電図（ERG）及び網膜神経節、網膜外顆粒層の肥厚が改善されることを示した。本成果が点眼による網膜症治療薬開発に繋がることを期待する。研究成果の概要（英文）：Retinopathy leads to irreparable vision loss via capillary closure and areas of nonperfusion. In this study, we prepared ophthalmic formulations containing nilvadipine nanoparticles (NIL-NPs), and demonstrated whether the instillation of NIL-NPs can prevent retinal dysfunction in rats injected with excessive streptozotocin (STZ rats). NIL-NPs was prepared by wet bead mill treatment, and the mean particle size was 77 nm. Changes in retinal function were evaluated by electroretinogram (ERG) and immunological methods. The instillation of NIL-NPs allowed the topical supplement of nilvadipine into the retina, and repetitive instillation of NIL-NPs (2times/day for 1 week) attenuated the retinal disorders led by the excessive streptozotocin. An ophthalmic drug delivery system using drug nanoparticles may be useful the application for therapy of retinopathy.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：基盤研究(C);  研究期間：2018～2020;   課題番号：18K06769;   研究分野：医療薬学;   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ(WEKO2)","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Nagai, Noriaki"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学薬学部; 准教授"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"長井, 紀章"},{"creatorName":"ナガイ, ノリアキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-08"}],"displaytype":"detail","filename":"18K06769seika.pdf","filesize":[{"value":"660.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"18K06769seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/22134/files/18K06769seika.pdf"},"version_id":"35e36137-c17f-41c0-a476-ec43f973755a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ナノ結晶製剤","subitem_subject_scheme":"Other"},{"subitem_subject":"網膜","subitem_subject_scheme":"Other"},{"subitem_subject":"点眼製剤","subitem_subject_scheme":"Other"},{"subitem_subject":"界面活性剤","subitem_subject_scheme":"Other"},{"subitem_subject":"糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"バイオアベイラビリティ","subitem_subject_scheme":"Other"},{"subitem_subject":"ビーズミル","subitem_subject_scheme":"Other"},{"subitem_subject":"湿式破砕","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"眼深部組織を標的とした次世代型ナノ点眼製剤の開発と網膜症治療への応用","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"眼深部組織を標的とした次世代型ナノ点眼製剤の開発と網膜症治療への応用","subitem_title_language":"ja"},{"subitem_title":"Design of new ophthalmic formulations based on drug nanoparticles and it's application for therapy of retinopathy","subitem_title_language":"en"}]},"item_type_id":"8","owner":"3","path":["4710"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-11-08"},"publish_date":"2021-11-08","publish_status":"0","recid":"22134","relation_version_is_last":true,"title":["眼深部組織を標的とした次世代型ナノ点眼製剤の開発と網膜症治療への応用"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-08-13T06:21:50.226792+00:00"}